Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Pescara

64 clinical trials in Pescara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pescara at a glance
64
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

64 trials in Pescara

Open in trial search

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Mantle cell lymphoma

Recruiting

Study of glofitamab, obinutuzumab and tocilizumab in patients with mantle cell lymphoma relapsed or refractory after CAR‑T therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Fondazione Italiana Linfomi Ets

Acute lymphocytic leukaemia

Recruiting

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Mantle cell lymphoma

Recruiting

A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Fondazione Italiana Linfomi Ets

Acute myeloid leukaemia

Recruiting

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Recruiting

Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Medizinische Hochschule Hannover

Colitis ulcerative+1

Recruiting

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Acute myeloid leukaemia

Recruiting

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Gilteritinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Secondary immunodeficiency

Recruiting

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Pescara

What the registry says about research in the country

01 Hematologic Malignancies

Clinical trials focusing on acute myeloid leukemia (AML) and multiple myeloma, evaluating novel therapeutic approaches including chemotherapy-free alternatives and targeted treatments.

  • Leukemia therapies
  • Novel drug combinations
  • Targeted treatments

Studies explore innovative treatment strategies, including venetoclax combinations and immunotherapy approaches.

02 Lymphoma Research

Investigations into follicular lymphoma and diffuse large B-cell lymphoma, testing shortened chemotherapy protocols combined with immunotherapy treatments.

  • Immunotherapy protocols
  • Treatment optimization
  • Response assessment

Research aims to improve treatment outcomes while reducing therapy duration and side effects.

03 Pediatric Oncology

Studies addressing acute lymphoblastic leukemia in children and adolescents, evaluating new treatment protocols and maintenance strategies.

  • Childhood leukemia
  • Lymphoblastic lymphoma
  • Treatment protocols

Focus on developing more effective and less toxic treatment approaches for young patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.